Medical 21 Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • Angel

  • (Announced)
  • Latest Deal Amount
  • $40M

Medical 21 General Information

Description

Developer of an artificial graft designed to use in coronary bypass heart surgeries. The company's products include an artificial blood vessel as an alternative to harvesting blood vessels for coronary artery bypass surgeries, enabling cardio surgeons to make cardiac bypass surgery easier for patients and less expensive for the healthcare system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Primary Office
  • 15070 23rd Avenue North
  • Minneapolis, MN 55447
  • United States
+1 (612) 000-0000

Medical 21 Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medical 21 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Angel (individual) 28-Apr-2022 $40M 0000 00000 Announced Pre-Clinical Trials
5. Later Stage VC 15-Sep-2022 00.00 0000 Completed Pre-Clinical Trials
4. Seed Round 30-Apr-2021 00.00 00.00 Completed Pre-Clinical Trials
3. Seed Round 15-May-2019 00.000 000 Completed Pre-Clinical Trials
2. Angel (individual) 01-Sep-2017 $250K $2.25M Completed Pre-Clinical Trials
1. Seed Round 31-Mar-2017 $2M $2M Completed Pre-Clinical Trials
To view Medical 21’s complete valuation and funding history, request access »

Medical 21 Patents

Medical 21 Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10954540-B2 Methods of producing biosynthetic bacterial cellulose membranes Active 11-Dec-2015 000000000
EP-3386554-A4 Methods of producing biosynthetic bacterial cellulose membranes Pending 11-Dec-2015 000000000
EP-3386554-A1 Methods of producing biosynthetic bacterial cellulose membranes Pending 11-Dec-2015 000000000
AU-2016366783-B2 Methods of producing biosynthetic bacterial cellulose membranes Active 11-Dec-2015 000000000
AU-2016366783-A1 Methods of producing biosynthetic bacterial cellulose membranes Active 11-Dec-2015 C12P19/04
To view Medical 21’s complete patent history, request access »

Medical 21 Executive Team (1)

Name Title Board Seat Contact Info
Manny Villafana Ph.D Founder, Chief Executive Officer & Chairman
To view Medical 21’s complete executive team members history, request access »

Medical 21 Board Members (1)

Name Representing Role Since
Manny Villafana Ph.D Medical 21 Founder, Chief Executive Officer & Chairman 000 0000
To view Medical 21’s complete board members history, request access »

Medical 21 Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial